NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- HLA-A*2402-restricted VEGFR1/2 multipeptide vaccine
- A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from vascular endothelial growth factor receptors (VEGFRs) 1 and 2. Upon administration, this peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR1- and VEGFR2-expressing tumor cells, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)